Epigenomics AG (STU:ECX) 3-Year Revenue Growth Rate : -50.00% (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Epigenomics AG 3-Year Revenue Growth Rate?

Epigenomics AG's Revenue per Share for the three months ended in Jun. 2023 was €0.08.

During the past 12 months, Epigenomics AG's average Revenue per Share Growth Rate was -92.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was -50.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -34.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was -22.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Epigenomics AG was 20.10% per year. The lowest was -50.00% per year. And the median was -10.30% per year.

Competitive Comparison of Epigenomics AG's 3-Year Revenue Growth Rate

For the Diagnostics & Research subindustry, Epigenomics AG's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Epigenomics AG's 3-Year Revenue Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's 3-Year Revenue Growth Rate falls into.

Epigenomics AG 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Epigenomics AG (STU:ECX) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Epigenomics AG 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Epigenomics AG (STU:ECX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (STU:ECX) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

EPGNF:USA

Address

Geneststrasse 5, Berlin, BB, DEU, 10829

Website

https://www.epigenomics.com

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.